1. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial;Duchesne;Lancet Oncol,2016
2. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline;Loblaw;J Clin Oncol,2007
3. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015
4. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014
5. Alpha emitter radium-223 and survival in metastatic prostate cancer;Parker;N Engl J Med,2013